

> d his

(FILE 'HOME' ENTERED AT 10:51:57 ON 03 JUN 2004)

FILE 'CAPLUS' ENTERED AT 10:53:58 ON 03 JUN 2004

L1 0 S WO20059486/PN
L2 1 S WO200059486/PN
SELECT L2 1 RN
L3 110742 S E1-E81
L4 1188 S L3 AND ?PROPANOL

FILE 'REGISTRY' ENTERED AT 10:57:36 ON 03 JUN 2004

L5 1 S 136817-59-9/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 10:58:59 ON 03 JUN 2004

L6 1 S 134234-12-1/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 11:03:11 ON 03 JUN 2004

L7 1 S 133454-47-4/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 11:03:24 ON 03 JUN 2004

L8 46 S L6
L9 2 S L8 AND NK1
L10 51 S L6 OR CP(W) (101606 OR 98113) OR TRAXOPRODIL
L11 15 S L10 NOT PY>=1999
S 145742-28-5/REG# OR QUINIDINE OR CHINIDIN OR CONCHININ? OR C

FILE 'REGISTRY' ENTERED AT 11:25:08 ON 03 JUN 2004

L12 1 S 18786-24-8/RN

FILE 'CAPLUS' ENTERED AT 11:25:08 ON 03 JUN 2004

L13 251 S L12

FILE 'REGISTRY' ENTERED AT 11:25:09 ON 03 JUN 2004

L14 1 S 145742-28-5/RN

FILE 'CAPLUS' ENTERED AT 11:25:09 ON 03 JUN 2004

L15 58 S L14
L16 7045 S L15 OR QUINIDINE OR CHINIDIN OR CONCHININ? OR CONQUININE OR C
L17 2 S L10 AND L16
L18 2342 S SERTRALINE OR VENLAFAXINE OR DEXMEDETOMIDINE OR TRIPENNELAMIN
L19 1 S L18 AND L10
L20 549 S L18 AND NEURO?
L21 217 S L20 NOT PY>=1999
L22 6 S L21 AND US/PC

FILE 'REGISTRY' ENTERED AT 11:51:53 ON 03 JUN 2004


E SERTRALINE/CN
L23 1 S E3

FILE 'CAPLUS' ENTERED AT 11:52:30 ON 03 JUN 2004

L24 1275 S L23 OR SERTRALINE OR CP(W) 51974
L25 213 S L24 AND US/PC
L26 43 S L25 AND NEURO?
L27 5 S L26 NOT PY>=1999

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 134234-12-1 REGISTRY
 CN 1-Piperidineethanol, 4-hydroxy- α -(4-hydroxyphenyl)- β -methyl-4-phenyl-, (α S, β S)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1-Piperidineethanol, 4-hydroxy- α -(4-hydroxyphenyl)- β -methyl-4-phenyl-, [S-(R*,R*)]-
 OTHER NAMES:
 CN (+)-CP 101606
 CN CP 101606
 CN CP 98113
 CN Traxoprodil
 FS STEREOSEARCH
 MF C20 H25 N O3
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSRESEARCH, PHAR, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 DT.CA CAPLUS document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

46 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 46 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s wo200059486/pn
L2          1 WO200059486/PN
           (WO2000059486/PN)
```

```
=> select l2
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
E1 THROUGH E81 ASSIGNED
```

```
=> s e1-e81
      846 10262-69-8/BI
     5538 10540-29-1/BI
      273 106133-20-4/BI
     1160 106266-06-2/BI
      538 1131-64-2/BI
      434 113775-47-6/BI
      794 114-86-3/BI
      117 115956-12-2/BI
      157 124937-51-5/BI
      609 125-28-0/BI
      772 125-29-1/BI
     1431 125-71-3/BI
       10 131831-03-3/BI
       51 133454-47-4/BI
       46 134234-12-1/BI
     1209 13655-52-2/BI
      336 136817-59-9/BI
       58 145742-28-5/BI
     1409 155213-67-5/BI
     1364 2062-78-4/BI
       87 2165-19-7/BI
     1458 24219-97-4/BI
       130 25905-77-5/BI
     1265 26839-75-8/BI
       219 26844-12-2/BI
       741 27203-92-5/BI
       384 27848-84-6/BI
       243 29216-28-2/BI
       676 298-57-7/BI
     2050 303-49-1/BI
       784 31828-71-4/BI
       643 3239-44-9/BI
       46 35080-11-6/BI
       209 37640-71-4/BI
     1255 42542-10-9/BI
       732 483-04-5/BI
     4512 50-47-5/BI
     4287 50-48-6/BI
     6757 50-49-7/BI
     2145 50-52-2/BI
     1794 51-06-9/BI
     2576 51384-51-1/BI
     8540 52-86-8/BI
       964 52468-60-7/BI
    11233 525-66-6/BI
     3740 537-46-2/BI
       175 53772-83-1/BI
     4288 54-05-7/BI
       632 54063-53-5/BI
       469 54143-55-4/BI
       970 54739-18-3/BI
     2877 54910-89-3/BI
     4079 56-54-2/BI
       338 5633-20-5/BI
```


1664 58-39-9/BI
3453 60-87-7/BI
1506 61869-08-7/BI
103 62498-67-3/BI
93 63638-91-5/BI
236 64-13-1/BI
174 6621-47-2/BI
119 66778-36-7/BI
726 68-88-2/BI
261 69756-53-2/BI
441 71320-77-9/BI
1991 72-69-5/BI
725 76-42-6/BI
5029 76-57-3/BI
1036 76-58-4/BI
66 77518-07-1/BI
1005 79617-96-2/BI
159 80012-43-7/BI
372 83-74-9/BI
95 83015-26-3/BI
485 89565-68-4/BI
1886 90-39-1/BI
33518 9035-51-2/BI
915 91-81-6/BI
250 93-30-1/BI
679 93413-69-5/BI
1061 99614-02-5/BI

L3

110742 (10262-69-8/BI OR 10540-29-1/BI OR 106133-20-4/BI OR 106266-06-2/BI OR 1131-64-2/BI OR 113775-47-6/BI OR 114-86-3/BI OR 115956-12-2/BI OR 124937-51-5/BI OR 125-28-0/BI OR 125-29-1/BI OR 125-71-3/BI OR 131831-03-3/BI OR 133454-47-4/BI OR 134234-12-1/BI OR 13655-52-2/BI OR 136817-59-9/BI OR 145742-28-5/BI OR 155213-67-5/BI OR 2062-78-4/BI OR 2165-19-7/BI OR 24219-97-4/BI OR 25905-77-5/BI OR 26839-75-8/BI OR 26844-12-2/BI OR 27203-92-5/BI OR 27848-84-6/BI OR 29216-28-2/BI OR 298-57-7/BI OR 303-49-1/BI OR 31828-71-4/BI OR 3239-44-9/BI OR 35080-11-6/BI OR 37640-71-4/BI OR 42542-10-9/BI OR 483-04-5/BI OR 50-47-5/BI OR 50-48-6/BI OR 50-49-7/BI OR 50-52-2/BI OR 51-06-9/BI OR 51384-51-1/BI OR 52-86-8/BI OR 52468-60-7/BI OR 525-66-6/BI OR 537-46-2/BI OR 53772-83-1/BI OR 54-05-7/BI OR 54063-53-5/BI OR 54143-55-4/BI OR 54739-18-3/BI OR 54910-89-3/BI OR 56-54-2/BI OR 5633-20-5/BI OR 58-39-9/BI OR 60-87-7/BI OR 61869-08-7/BI OR 62498-67-3/BI OR 63638-91-5/BI OR 64-13-1/BI OR 6621-47-2/BI

L23 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 79617-96-2 REGISTRY

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN 1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-,
(1S,4S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-,
(1S-cis)-

OTHER NAMES:

CN (+)-Sertraline

CN CP 51974

CN **Sertraline**

=> s l10 and l16
L17 2 L10 AND L16

=> d ibib abs 1-2

L17 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:725447 CAPLUS
DOCUMENT NUMBER: 133:301178
TITLE: Use of CYP2D6 inhibitors in combination therapies
INVENTOR(S): Obach, Ronald Scott
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059486	A2	20001012	WO 2000-IB304	20000320
WO 2000059486	C1	20020725		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000009564	A	20020108	BR 2000-9564	20000320
EP 1242058	A1	20020925	EP 2000-909570	20000320
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
EE 200100524	A	20021216	EE 2001-524	20000320
JP 2003523936	T2	20030812	JP 2000-609050	20000320
US 2003144220	A1	20030731	US 2000-528978	20000321
HR 2001000722	A1	20020831	HR 2001-722	20011004
ZA 2001008158	A	20030724	ZA 2001-8158	20011004
NO 2001004858	A	20011205	NO 2001-4858	20011005
BG 106075	A	20020628	BG 2001-106075	20011101
US 2004018253	A1	20040129	US 2003-622301	20030718
US 2004028755	A1	20040212	US 2003-624123	20030721

PRIORITY APPLN. INFO.:
US 1999-128136P P 19990407
WO 2000-IB304 W 20000320
US 2000-528978 A3 20000321

AB This invention relates to the use of a CYP2D6 inhibitor in combination with a drug having CYP2D6-catalyzed metabolism, wherein the drug and the CYP2D6 inhibitor are not the same compound; and pharmaceutical compns. for said use.

L17 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:351162 CAPLUS
DOCUMENT NUMBER: 133:790
TITLE: New use of glutamate antagonists for the treatment of cancer
INVENTOR(S): Ikonomidou, Hrissanthi
PATENT ASSIGNEE(S): Germany
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1002535	A1	20000524	EP 1998-250380	19981028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 9964750	A1	20000515	AU 1999-64750	19991022
EP 1124553	A1	20010822	EP 1999-952622	19991022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002528415	T2	20020903	JP 2000-578005	19991022
PRIORITY APPLN. INFO.:				
			EP 1998-250380	A 19981028
			WO 1999-EP8004	W 19991022
AB New therapies can be devised based upon a demonstration of the role of glutamate in the pathogenesis of cancer. Inhibitors of the interaction of glutamate with the AMPA, kainate, or NMDA receptor complexes are likely to be useful in treating cancer and can be formulated as pharmaceutical compns. They can be identified by appropriate screens.				
REFERENCE COUNT:		8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	